Gene Therapy Medical Affairs Summit

th (2)
Transforming Traditional Medical Affairs to Launch the Next Generation of Breakthrough Gene Therapy Products

Speakers

Kent-Christopherson-Orchard-Tx-150x150
Kent Christopherson
Senior Director
Kent-Christopherson-Orchard-Tx-150x150
Sue Lacey
Scientific & Medical Affairs Consultant
1609647825523
Nick Li Senior
Director
Salvador_Rico-Encoded-Tx-150x150
Salvador Rico
Chief Medical Officer
1558461281808
Jodie Gillon
Chief Patient Office
1589663663040
Stephen Kagen
Global Medical Lead
1517734602224
Eileen Sawyer
Vice President
1560449800557
Jennifer Aikin
Head of Global Medical Affairs Training
1516293417009
Carol Hoang
Vice President
1602104278191
Laura Campbell
Senior Medical Directo
1517710284207
Tom Pulles
Vice President
1580417285883
Rita Zambelas
Medical Science Liaison
1538598602431
Marcus Droege
Vice President
1581462684869
Angela Tom
Medical Director
th
Ian Winburn
Global Medical Lead
1604936665147
Crecia Magee, CPC
President, Principal Talent Executive
1544089380487
Daniel Snyder
VP Medical Affairs
1516331085075
William Bakker
Sr Medical Science Liaison

Start

February 9, 2021

End

February 11, 2021

Address

Online Event   View map

Transforming Traditional Medical Affairs to Launch the Next Generation of Breakthrough Gene Therapy Products
The inaugural Gene Therapy Medical Affairs Summit is dedicated to exploring the pivotal internal and external role that Medical Affairs plays in delivering gene therapies to patients.

Industry pioneers from leading pharma and biotech companies at various stages of development and commercialization including Novartis Gene Therapy, Orchard Therapeutics & Bluebird Bio will share how to engage effectively with internal clinical and commercial teams as well as external HCPs, regulators and patient advocates to create a cohesive and streamlined launch strategy for complex, high priced gene therapy products and ultimately work to remove both barriers that exist for access to gene therapies.

Join this definitive, niche conference to delve into the unique Medical Affairs challenges encountered when working with gene therapies, from adapting to the clinical realities of the rare disease space to handling long-term follow up and post-launch scrutiny, equipping you with the insights required to launch gene therapy products more efficiently and effectively than ever before.

This virtual event is set to be a highly interactive and engaging meeting. We fully understand (and quite frankly agree) that a presentation-heavy conference just isn’t up to scratch! As such we have created a new format for this meeting which maximises opportunities for engagement, discussion, and Q&A’s in order for you to get the best value from this meeting.

Access the official agenda for more information.